AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for Wet Age-Related Macular Degeneration Treatment
ByAinvest
Tuesday, Jul 29, 2025 7:01 am ET1min read
EyePoint Pharmaceuticals has completed enrollment of its Phase 3 pivotal program for DURAVYU in wet age-related macular degeneration (AMD). The LUCIA trial enrolled over 400 patients in seven months, making it one of the fastest enrolling Phase 3 programs for wet AMD. Interim analysis confirmed no changes to the protocol and recommended continuation of the trial. Topline 56-week data for LUGANO is expected in mid-2026, with LUCIA to follow closely. DURAVYU has demonstrated a favorable safety and tolerability profile in over 190 patients across four clinical trials.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet